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Abstract
Background—Inherited genetic variations offer a possible explanation for the observed
peculiarities of stroke in sub – Saharan African populations. Interleukin–6 polymorphisms have
been previously associated with ischemic stroke in some non-African populations.

Author Manuscript

Aim—Herein we investigated, for the first time, the association of genetic polymorphisms of IL-6
and CDKN2A- CDKN2B and other genes with ischemic stroke among indigenous West African
participants in the Stroke Investigative Research and Education Network (SIREN) Study.
Methods—Twenty-three previously identified single nucleotide polymorphisms (SNPs) in 14
genes of relevance to the neurobiology of ischemic stroke were investigated. Logistic regression
models adjusting for known cardiovascular disease risk factors were constructed to assess the
associations of the 24 SNPs in rigorously phenotyped cases (N=429) of ischemic stroke (Men =
198; Women = 231) and stroke– free (N=483) controls (Men = 236; Women = 247).

Author Manuscript

Results—Interleukin-6 (IL6) rs1800796 (C minor allele; frequency: West Africans = 8.6%) was
significantly associated with ischemic stroke in men (OR = 2.006, 95% CI = [1.065, 3.777], p =
0.031) with hypertension in the model but not in women. In addition, rs2383207 in CDKN2A/
CDKN2B (minor allele A with frequency: West Africans = 1.7%) was also associated with
ischemic stroke in men (OR = 2.550, 95% CI = [1.027, 6.331], p = 0.044) with primary covariates
in the model, but not in women. Polymorphisms in other genes did not show significant
association with ischemic stroke.
Conclusion—Polymorphisms rs1800796 in IL6 gene and rs2383207 in CDKN2A/CDKN2B
gene have significant associations with ischemic stroke in indigenous West African men.
CDKN2A/CDKN2B SNP rs2383207 is independently associated with ischemic stroke in
indigenous West African men. Further research should focus on the contributions of inflammatory
genes and other genetic polymorphisms, as well as the influence of sex on the neurobiology of
stroke in people of African ancestry.
Keywords
Interleukin-6; Candidate Gene; Stroke; West Africa

Author Manuscript

INTRODUCTION
Stroke is the clinical culmination of complex biological processes and interacting pathways
that involve non–genetic and genetic factors.1 In fact, the burden of stroke has significant
race-ethnic and geographic disparities, with individuals of African ancestry being at higher
risk, and experiencing poorer outcomes than most other racial groups in the world.2–5
Inherited genetic variations offer a possible explanation for the observed peculiarities of
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stroke in sub – Saharan African populations, as well as the proportion of risk that remains
unexplained by traditional and emerging risk factors alone.6
Through multiple approaches including candidate gene, linkage studies, genome wide
association studies (GWAS) and whole exome sequencing, multiple susceptibility loci for
stroke have now been identified especially in populations of European ancestry, with fewer
studies among African Americans, and very little data on indigenous sub – Saharan
Africans.6 Thus, the Stroke Investigative Research and Education Network (SIREN) study is
exploring genetic factors in stroke among West Africans using multi – level approaches.7 We
herein report the findings of a candidate gene study using genotype and phenotype data from
ischemic stroke and stroke – free controls recruited into the SIREN Study. We investigated
the association and effect sizes of 23 selected SNPs with the occurrence of ischemic stroke
among indigenous West Africans.

Author Manuscript

METHODS
Study Population, Patient Enrollment and Data Acquisition

Author Manuscript

The rationale and design of the SIREN study has been described elsewhere.7 Essentially, the
SIREN study is a multi-center case-control study involving several sites in Nigeria and
Ghana which was initiated in August 2014 with an initial recruitment target of 3000 cases
and 3000 controls. The ethnographic characteristics of the study population are described in
detail in supplementary table 1. The ethnic groups include the Yoruba (Ibadan and Abeokuta
sites in southern Nigeria), the Hausa (Kano and Zaria in Northern Nigeria), the Akan, Ewe
and Ga/Adangbe (Accra and Kumasi, Southern and Northern Ghana).10 Ethical approval
was obtained for all study sites and informed consent was obtained from all subjects. Cases
included consecutively recruited consenting adults (aged 18 years or older) with first clinical
stroke within 8 days of current symptom onset or ‘last seen without deficit’ with
confirmatory cranial CT or MRI scan performed within 10 days of symptom onset. We
excluded individuals with stroke mimics, primary subarachnoid hemorrhage and previous
strokes which were not ascertained by neuroimaging. Stroke-free status of controls recruited
for the SIREN was ascertained using a locally-validated version of the Questionnaire for
Verifying Stroke-Free Status (QVSFS) with a modification to include pictograms of stroke
symptoms with improved sensitivity and specificity.8,9

Author Manuscript

We collected basic demographic and lifestyle data including ethnicity and native language of
the subjects and their parents, socioeconomic status, dietary patterns, routine physical
activity, stress, depression, cigarette smoking, and alcohol use as well as cardiovascular and
anthropometric measurements using standard techniques. A detailed neurologic evaluation
was conducted to assess neurologic deficits and determine stroke severity using the National
Institute of Health Stroke Severity Score. Blood samples were collected from cases and
controls at baseline for measuring fasting lipid profile, blood glucose and HbA1c. Stroke
diagnosis and phenotyping was undertaken using the ACCESS software [Patent No:
NG/PT/NC/2016/2007] based on clinical evaluation and brain neuroimaging (brain CT or
MRI).
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Hypertension, diabetes mellitus, dyslipidemia, and central adiposity were used as
dichotomous covariates in the models and are described in Table 1. Dyslipidemia was
defined in accordance with the recommendations of the US National Cholesterol Education
Program10.
Selection of stroke candidate genes and SNPs

Author Manuscript

Through an extensive literature review 24 single nucleotide polymorphisms (SNPs) from 14
candidate genes with published and /or suspected association with ischemic stroke risk were
selected for genotyping (Table 2). Majority of these were SNPs already associated with
ischemic strokes and validated in at least more than one cohort. However, selection of the
APOL1 G1 [rs73885319 and rs60910145] was largely exploratory based on recent data
suggesting increasing role of the APOL1 in cardiovascular disease in people of African
ancestry.14
Genotyping and Quality Control Method

Author Manuscript

Genomic DNA was extracted from whole blood with Gentra Systems PUREGENE DNA
purification kit (Qiagen Group) according to manufacturers’ protocol. Genotyping was
carried out on genomic DNA from 506 stroke cases and 506 stroke free controls randomly
selected from among the entire cohort of recruited subjects as described above. The
genotyping was performed at Northwest Genomics Center in Washington Seattle, USA,
using an ABI TaqMan SNP genotyping assays by Design (Applied Systems) under
conditions recommended by the manufacturer. Probe and primer sequences for each assay
are available on request. The assays were originally selected for 24 published vascular
disease-associated single nucleotide polymorphisms (SNPs) (Table 2) and included 3 SNPs
on pro-inflammatory genes (IL6 and CD14) genes which have been previously reported to
be associated with ischemic stroke in African Americans. Standard quality control
procedures were applied to the genotype data using all SNPs on the chip. We also genotyped
sickle cell SNP rs334 to control for confounding due to sickle cell trait.
Excluded subjects

Author Manuscript

After rigorous quality control of genotype data, individuals with sex discordance between
reported and observed from genetic data and 44 cases with hemorrhagic stroke were
excluded. There were 4 samples with sickle cell anemia and 5 samples with missing
genotype for rs334 (Supplementary Table 2). After excluding participants whose genotype
data did not pass quality control, the study sample consisted of 912 subjects (429 ischemic
stroke cases and 483 stroke – free controls).
Power calculation
With the 429 cases and 483 controls, we can observe minimum OR of 2.8 with correction
for multiple testing (α=0.05/23=0.002) with allele frequency as low as 0.02. However, we
can observe minimum OR of 2.06 with correction for multiple testing (α=0.05/23=0.002)
with allele frequency as low as 0.05.
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All statistical analyses were performed using PLINK1.9. We compared proportions or means
by two-sided t-tests and for stratified samples with respect to sex we used χ2 tests or
Fisher’s exact test if the cell size was less than 5. All SNPs were in Hardy-Weinberg
equilibrium except rs60910145 in APOL1 gene (p= 2.3 × 10−6) (Supplementary Table 3). To
test for associations between ischemic stroke status and each single SNP, we fitted logistic
regression models in which each SNP was modeled as a predictor variable whose values
were equal to the number of copies of the minor allele (0, 1, 2) (i.e., additive mode of
inheritance). The primary fitted model included age, sex ethnicity and rs334 (sickle cell
status) as covariates. Majority of the individuals were from Akan, Yoruba, and Hausa. The
other ethnicities were combined as one to avoid small sample size issues within each
categories. Ethnicity was modeled as categorical variable. Recruitment site was not
significant in any of our analysis due to strict protocol followed at each site. Therefore, we
did not use site in the model. Furthermore, we also performed sex stratified logistic
regression because of reported gender disparities in stroke prevalence, incidence, severity
and outcomes.5,15–17 In the primary sensitivity analysis model, we added history of
hypertension, while in the secondary model we further added dichotomous variables for
diabetes, dyslipidemia, and waist-hip as predictors defined in table 1 step-wisely to ascertain
whether these covariates had independent effects. The statistical models are described below.
Analyzed Models

Author Manuscript

•

Model 1 (Primary Model): SNP + Age + Sickle-Cell Status + Ethnicity

•

Model 2 (Model 1 + Hypertension): SNP + Age + Sickle-Cell Status +
Ethnicity + Hypertension

•

Model 3 (Model 2 + Diabetes): SNP + Age + Sickle-Cell Status + Ethnicity +
Hypertension + Diabetes

•

Model 4 (Model 3 + Dyslipidemia): SNP + Age + Sickle-Cell Status +
Ethnicity + Hypertension + Diabetes + Dyslipidemia

•

Model 5 (Model 4 + waist-hip-ratio): SNP + Age + Sickle-Cell-Status +
Ethnicity + Hypertension + Diabetes + Dyslipidemia + waist-hip-ratio

In addition, we ran exact logistic regression analysis to ensure that our results were not
affected by small or zero cell counts for covariates used in the sensitivity analysis.

RESULTS
Author Manuscript

Subject Characteristics and Distribution of Covariates
The demographic and risk factor characteristics by case-control status are described in Table
3. The mean age of the subjects with ischemic stroke was 61.34 (±12.83) years while the
mean age of stroke – free control subjects was 60.26 (± 12.56) years (p =0.2001). Cases
were significantly more likely than controls to have a history of hypertension (90% vs. 42%)
(p <0.0001), diabetes (39% vs 14%) (p <0.0001), dyslipidemia (87% vs. 58%) (p <0.0001)
and abnormal waist – hip ratio (25% vs. 11%) (p <0.0001), whereas there were no
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statistically significant differences between cases and controls with respect to age (p=0.233),
sex (p=0.4528), ethnicity (p: 0.0830 – 0.8871), and recruitment site (p: 0.192 – 1.000). The
ischemic stroke subtypes are as shown in Table 3. Hypertension is often undiagnosed in the
population, and so duration as well as family history may not be accurate. However, known
family history of hypertension in parents or siblings was absent in 300 cases and 394
controls. Smoking and atrial fibrillation were not important risk factors in this population.
The percentage of those with atrial fibrillation was <5% while smoking was also rare. Waist
– hip ratio was included as a measure of obesity rather than BMI (Table 3).
Genotyping

Author Manuscript

We genotyped 23 candidate SNPs in 14 genes that have been previously associated with
stroke risk (Table 2), including APOL1 G1 SNP variants and HBB SNP rs334 (a surrogate
SNP for sickle cell anemia). Genotypic distribution of rs334 is provided in Supplementary
Table 2. SNP rs74475935 in candidate gene ABCC1 was missing in all individuals due to
failed assay and SNP rs60910145 in APOL1 was not in HWE (p=2.3E-6). Details of the
minor allele and its frequency in both cases and controls, genotypic distribution of each SNP
in controls, HWE p-values, gene names reported by ANNOVAR, SNP function,
comparisons of allele frequencies with 1000 Genome project populations, and functional
score CADD are described in Supplementary Table 3.
Association

Author Manuscript
Author Manuscript

We did not observe any significant association with stroke when case-control analysis was
done using sex and other covariates in the primary logistic regression model as described in
the methods section. However, when we analyzed case-control sex-stratified data, we
observed rs1800796 in IL-6 (minor allele C with frequency=8.6% in controls and 9.4% in
cases (OR=1.645; 95% CI: 0.971–2.789; p-value=0.065) and rs2383207 in CDKN2A/
CDKN2B (minor allele A with frequency=1.7% in controls and 2.7% in cases) was
significant with p-value=0.044 (OR=2.550; 95% CI: 1.027–6.331) with only primary
covariates in the model. The effect sizes and p-values for both SNPs are detailed in Table 4
including sensitivity analyses. In the sensitivity analysis, rs1800796 in IL-6 was significant
with p-value=0.031 (OR=2.006; 95% CI: 1.065–3.777) with hypertension in the model; pvalue=0.038 (OR=1.957; 95% CI: 1.038–3.690) with the addition of diabetes to the model;
p-value=0.051 (OR=1.886; 95% CI: 0.998–3.564) with further addition of dyslipidemia to
the model; and p-value (p=0.132) was not significant when we finally added waist-hip-ratio.
Similarly, rs2383207 in CDKN2A/CDKN2B was not significant with hypertension,
diabetes, and dyslipidemia in the model. However, the rs2383207 in CDKN2A/CDKN2B
became significant when we added waist-hip-ratio to the model. The results for male only
analyses for all SNPs are detailed in the Supplementary Table 4 and the results for nongenetic covariates are given in the Supplementary Tables 5 and 6 for SNPs rs1800796 and
rs2383207, respectively. Furthermore the significance of IL6 SNP was confirmed using
exact logistic regression with 20K burn in and 100K interactions with the primary model as
well as when the models included other covariates (Supplementary Table 7). The association
of rs2383207 in CDKN2B-AS1 was not significant with the primary model, inclusion of
hypertension and diabetes. However, rs2383207 was significant with p-value 0.044 with
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inclusion of dyslipidemia in the model. In supplementary table 8, we compare the effect size
and direction for IL-6 SNP rs1800796 with previous reports.

Author Manuscript

In the step-wise analyses, ethnicity, hypertension, dyslipidemia, diabetes, and waist-hip ratio
risk were significant irrespective of SNP in the model (Supplementary Table 5). Specifically,
in the final model with all covariates and rs1800796 in the model, ethnicity (Akan: p=0.004;
Hausa: p=0.004; and other: p=0.733), hypertension (3.93E-15), diabetes (p=0.039),
dyslipidemia (1.77E-05), and waist-hip ratio risk (p=0.004). Also in the final model with all
covariates and rs2383207 in the model ethnicity (Akan: p=0.006; Hausa: p=0.005; and other:
p=0.635), hypertension (p=8.17E-15), diabetes (p=0.038), dyslipidemia (p=6.23E-06), and
waist-hip ratio risk (p=0.001). Thus, it implies that ethnicity, hypertension, dyslipidemia,
diabetes, and waist-hip ratio risk were independent predictors of ischemic stroke. We did not
include smoking and atrial fibrillation in the regression models because they were not
important stroke risk factors in this population. The percentage of those with atrial
fibrillation was <5% and smoking was also rare (Table 3). We also did not include family
history and duration of hypertension in the regression analysis model because they were
largely presumed. Note that Yoruba sample was the largest sample, so the program used
Yoruba sample as a reference sample in the analysis.
To see whether the difference of SNP-stroke association between sex-stratified analyses was
significant or it was due to small sample size, we included SNP by sex interaction in the
final model without sex-stratified sample and observed the following results: The interaction
p-values for sex × rs1800796 and sex × rs2383207 were 0.08 and 0.06 respectively showing
marginal significance. The female − specific sex-stratified logistic regression analysis results
are shown in Supplementary Table 8.

Author Manuscript

DISCUSSION
In this first ever case – control study of genetic polymorphisms associated with ischemic
stroke among West Africans, we found that the polymorphisms rs1800796 in the
interleukin–6 gene and rs2383207 in the CDKN2A/CDKN2B gene were associated with
nominal significance with the occurrence of ischemic stroke in men. This also represents the
first report of the analysis of association of any inflammatory genetic polymorphism
(rs1800796) and cardiovascular polymorphism (rs2383207) with stroke occurrence in sub–
Saharan Africa.

Author Manuscript

The finding of the significant association between IL-6 rs1800796 and ischemic stroke is
congruent with previous reports of similar association of IL-6 polymorphisms with ischemic
stroke among African American21, American Caucasian22 Japanese23 northern Chinese
Han24,25 and northern Indian26 populations. The odds ratio reported in this study lies within
the range of 1.40 – 2.50 previously reported in other studies21–26, noting that differences in
effect size may be due to differences in sample size and the sex – stratified analysis
undertaken in the present study (Table 5). The IL-6 promoter gene polymorphisms G174C
(rs1800795),C572G (rs1800796) and IL6 rs2069832 have been particularly associated with
the occurrence of ischemic stroke21,27 while IL6 rs2069830 was protective against ischemic
stroke among African American non – smokers in a biracial study.21 While previous studies
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did not conduct stratified analysis to explore the effect of sex, the significant association
between IL-6 rs1800796 gene and rs2383207 CDKN2A/CDKN2B and ischemic stroke in
men only agrees with a recent study of Li et al. (2015) using integrated microarray datasets,
in which IL-6 gene expression was significantly upregulated in male patients but down –
regulated in female patients.28 This evidence provides a possible genetic basis for gender
disparity in the epidemiology of stroke5,15,16,29,30.

Author Manuscript
Author Manuscript

The human interleukin – 6 (IL-6) gene is located on chromosome 7p21 and consists of 5
exons and 4 introns. The promoter polymorphisms of IL-6 regulate the circulating plasma
level of this pleiotropic cytokine which plays critical roles in the acute inflammatory
response and regulation of acute phase proteins such as C – reactive protein. It also
contributes to the inflammatory response by triggering endothelial dysfunction and
activating the coagulation – fibrinolysis system.22,31 Studies have demonstrated association
of serum levels of biomarkers of inflammation such as Interleukin – 6, C – reactive protein
and fibrinogen with such conditions as stroke, myocardial infarction and cardiovascular
deaths.22 Serum and cerebrospinal fluid IL–6 levels have also been associated with greater
stroke severity, larger infarct volume and worse functional outcomes as well as carotid artery
intima – media thickness, other vascular brain diseases (white matter hyperintensities and
lacunar infarction), vascular cognitive impairment and Alzheimer’s disease.27,32–34 Fine
particulate matter air pollution has been associated with elevated plasma levels of IL-6.35
The recently published report on the Global Burden of Disease 2013 (GBD 2013) study
demonstrated the significant contribution of household air pollution to the risk of stroke
especially in low and middle income countries, the largest risk been reported from the West
African sub – region.8 The significant association of IL- 6 polymorphism and stroke in this
study strengthens the putative contribution of air pollution (which triggers chronic
inflammation and atherosclerosis) to stroke risk in the West African sub- region, and this
warrants further detailed investigation.
The CDKN2A/CDKN2B gene is located in the intron of cyclin – dependent kinase inhibitor
2B anti sense RNA 136 and associated with type 2 DM and cerebral infarction (Table 2). It
was also implicated in large artery stroke in the COMPASS Consortium37. It became
significant in the current study when waist –hip-ratio was added to the sensitivity analysis in
the presence of ethnicity, hypertension, type 2 DM, and dyslipidemia. This might suggest a
possible confounding effect although waist-hip ratio was an independent predictor of stroke.
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The association of both IL- 6 and CDKN2A/CDKN2B genes with ischemic stroke have been
confirmed by the COMPASS consortium and other previous studies although there were no
specific data from stratified analysis based on gender and obesity.21–26 However, IL- 6 as a
multifunctional cytokine plays a key role in chronic inflammation and SNP rs1800796 is
associated with susceptibility to several diseases including breast cancer38,39, osteoarthritis40
and membranous glomerulopathy41. Furthermore, the sex disparity related to IL-6
polymorphisms is not limited to stroke but also influences susceptibility to other diseases.
One of such studies conducted in China suggested that rs1800796 polymorphism of the IL-6
gene was associated with susceptibility to HBV-related hepatocellular carcinoma in a male
Chinese Han population.42,43 Our rigorous association analysis which adequately controlled
for confounders and duly considered LD structure did not establish an association of APOE
J Neurol Sci. Author manuscript; available in PMC 2018 August 15.
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alleles with ischemic stroke in our cohort contrary to an earlier finding in a small Zambian
stroke cohort.44 The lack of association of the HBB rs334 and stroke in this study suggests
that the sickle cell carrier status may not be a significant risk factor for stroke in the
population under study.
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This study has limitations. We only evaluated a limited number of SNPs identified in prior
stroke genetic studies and were unable to study rare variants due to limited sample size and
thus lack of adequate power to observe small effect loci with multiple test correction
although our study had adequate power to detect larger effect loci. We would have needed
984 matched case-control pairs to observe an OR of 1.5 with minor allele frequency of 8.6%
(~0.09) similar to IL-6 rs1800796 while 3960 matched case-control pairs would have been
needed to observe an OR of 1.5 with minor allele frequency of 1.7% (~0.02) similar to
CDKN2A/CDKN2B rs2383207. Supplementary Table 9 shows sample size calculations
corresponding to an OR less than or equal to 1.5 and minor allele frequency varying from
0.01 to 0.2 to further illustrate the sample size limitation of our study to replicate the
associated candidate SNPs. Thirdly, we did not evaluate relationship with plasma protein
activity. Finally, we did not adjust for population structure due to unavailability of ancestry
informative markers in this current study. This is because we acknowledge that multi –
ethnicity raises the possibility that certain findings may result from the confounding effects
of genetic differences among populations. However, multi – ethnicity of the sample could
boost our understanding of the scope and generality of any findings, because pan-ethnic
replicability of association between a candidate SNP and trait outcome provides support for
a causal relationship.
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Another advantage of having an ethnically diverse sample is that patterns of linkage
disequilibrium may differ ethnically, helping to resolve causal from non-causal relationships.
While populations with high linkage disequilibrium may be useful for initial detection of
SNP associations, several different SNPs may be in strong or complete disequilibrium.
Populations with lower levels of disequilibrium can help resolve which SNP effect is
primary. Africans appear to have the lowest levels of linkage disequilibrium and hence are
likely to be most useful for such analyses.45 Certain SNPs have been previously detected in
stroke patients in other populations.46–48 Therefore, searching for such among diverse ethnic
groups in Africans and African Americans using the candidate gene approach is a good
starting point for exploring stroke genomics in this unique population.49,50

Author Manuscript

Our future work will examine our current findings and all current GWAS hits with greater
power and breadth within the context of a genome wide association studies on the entire
SIREN cohort of 6000 subjects, whole genome sequencing in an enriched sub-cohort of
familial small vessel disease (lacunar stroke), external validation of findings in other genetic
stroke cohorts and consortia, pathway – based analyses and functional genomic studies to
facilitate translational applications.

CONCLUSIONS/IMPLICATIONS
We observed that the polymorphisms rs1800796 in the interleukin-6 gene and rs2383207 in
CDKN2A/CDKN2B were associated with ischemic stroke in men with nominal significance
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but not women in West Africa. Certainly, further research is needed to more clearly
understand the contributions of sex, other inflammatory genes and other genetic
polymorphisms (including angiogenesis and obesity genes) to the neurobiology of stroke in
people of African ancestry.
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Refer to Web version on PubMed Central for supplementary material.
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Highlights
•

Polymorphisms rs1800796 in IL6 gene and rs2383207 in CDKN2A/
CDKN2B gene have significant associations with ischemic stroke in
indigenous West African men.

•

CDKN2A/CDKN2B SNP rs2383207 is independently associated with
ischemic stroke in indigenous West African men.

•

Abnormal waist-hip-ratio may be an important modifier interacting with
CDKN2A/CDKN2B gene to result in cerebral infarction among indigenous
West African men.
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Definition of dichotomous risk factors for stroke used as covariates in the statistical analysis.
Risk factor
Hypertension

Diabetes Mellitus

Dyslipidemia

Author Manuscript

Central Adiposity

Definition: If any of the outcomes within each category are met then risk is considered as Yes otherwise No.
•

Presence of sustained systolic BP≥140 mmHg or diastolic BP≥90 mmHg after onset of stroke

•

A history of hypertension

•

Taking antihypertensive medications before stroke.13

•

Previous history of diabetes mellitus

•

Use of medications for diabetes mellitus,

•

Fasting glucose levels≥126 mg/dl and/or HBA1c≥6.5%.10,13

•

High fasting serum total cholesterol ≥200 mg/dl

•

High Density lipoprotein (HDL)≤40 mg/dl10

•

Low Density Lipoprotein (LDL)≥130

•

Triglyceride(Trig) ≥ 150 mg/dl

•

History of use of statins before stroke were considered as risk to

•

stroke.

•

A waist–hip–ratio of ≥ 0.90 (men) and ≥ 0.85 (women)10
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zinc finger homeobox 3

cyclin dependent kinase
inhibitor

Interleukin – 6

Cluster of Differentiatio
n – 14
CDKN2B antisense
RNA 1
cadherin EGF LAG
seven-pass G-type
receptor 1
intergenic region near
TSPAN2
angiotensin I converting
enzyme

ZFHX3

CDKN2 A/CDKN2 B

IL6

CD14

ANRIL (CDKN2 B –
AS1)

CELSR1

intergeni c region near

ACE

TSPAN2

histone deacetylase 9

HDAC9

kappa-casein

CSN3
pituitary homeobox 2

Apolipoprote in E

APOE

PITX2

Gene Title

Gene

rs4343

rs1212234
1

TSPAN2 (distance=23569), NGF(distance=172847)

ACE

rs9615362
rs6007897
rs4044210*

rs1075727
8

rs2569190

rs2069832
rs2069830
rs1800796

rs1333040
rs1075727
4
rs2383207

rs1697145
6
rs 879324

rs1198404
1
rs2868879
1
rs2107595

rs2634073
rs2200733

rs3775745

rs429358
rs7412

CELSR1
CELSR1
CELSR1

CDKN2B-AS1 (distance=3384), DMRTA1(distance=322363)

CD14

IL6
IL6
IL6

CDKN2B-AS1
CDKN2B-AS1
CDKN2B-AS1

ZFHX3
ZFHX3

HDAC9
HDAC9 (distance=2613), TWIST1 (distance=115486)
HDAC9 (distance=12396), TWIST1 (distance=105703)

PITX2 (distance=102504), C4orf32(distance=1400770)
PITX2 (distance=146890),C4orf32(distance=1356 384)

CSN3

APOE
APOE

Gene Name (Reported by ANNOVAR)

SNPs

Author Manuscript

Selected published candidate genes and SNPs associated with ischemic stroke in adults.

Blood pressure regulation

Signal transduction and
neuroinflammati on

Transmembrane signaling

Epigenetic

Inflammation

Inflammation

Cell cycle regulation

Transcription factor

Transcription factor

Transcription factor

Immune and inflammatory
function

Lipid metabolism

Gene Ontology

ACE polymorphisms (A/G)
(previously studied in a Zambian

Associated with large artery
atherosclerosis in the SiGN
consortium GWAS8

Association with ischaemic stroke
confirmed among Japanese and
Chinese populations48

Association with CI confirmed37
among Chinese by GWAS

Interacts with smoking to
predispose to CI in African
Americans21

Associated with CI in African
Americans and Chinese
ancestry21,22

Associated with T2DM and CI in
Asians and confirmed in
Europeans37

Associated with atrial fibrillation
and CI in European ancestry.
Chinese ancestry and confirmed in
African Americans37

Associated with CI in European
ancestry and confirmed in African
Americans37

Associated with atrial fibrillation
and CI in European ancestry and
confirmed in African Americans37

Associated with CI in African
Americans by exome sequencing47

Previously associated with both CI
and ICH in Caucasians46 and East
Africans44

Justification/Reference

Author Manuscript
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Sickle cell

HBB*

Surrogate SNP for sickle cell

*

apolipoprotein L1

Author Manuscript

APOL1

Author Manuscript
HBB*

APOL1
APOL1

Gene Name (Reported by ANNOVAR)

rs334

rs7388531
9
rs6091014
5

SNPs

Author Manuscript

Gene Title

Cellular oxygen transport

Lipid metabolism

Gene Ontology

SNP codes for the sickle cell trait.
Increased risk of ischaemic stroke in
persons with sickle cell trait50

Exploratory. no specific studies yet
that have linked APOL1 to stroke,
emerging literature suggests carriers
of APOL1 variants may have higher
CVD burden49

stroke cohort) ACE exonic
synonymous variant p.T202T44

Justification/Reference

Author Manuscript

Gene

Akinyemi et al.
Page 16

J Neurol Sci. Author manuscript; available in PMC 2018 August 15.

Akinyemi et al.

Page 17

Table 3

Author Manuscript

Characteristics of the SIREN case-control samples after QC.
Variable

Status/Values

Author Manuscript

A : Controls
(N=483)

B: Cases
(N=429)

P-value comparing
A and B

Baseline Age (mean ± SD)

60.26 (± 12.56)

61.34 (± 12.83)

0.2001

SEX (M/F)

236/247

198/231

0.4528

Sickle-Cell Status

100/383

85/344

0.8016

Hypertension (Risk / N-Risk)

201/281

378/44

< 0.0001

Diabetes

67/415

166/260

< 0.0001

Dyslipidemia (Risk / No-Risk)

282/201

370/55

< 0.0001

Waist-Hip Ratio (Risk / No-Risk)

344/115

332/40

< 0.0001

Atrial Fibrillation (Yes/No)

0/483

13/417

<0.0001

Tobacco use (Yes/No)

1/476

14/410

0.0003

Akan

68/80

39/74

0.0830

Yoruba

119/109

117/112

0.8871

Ga/Adangbe/Igbo/Gonja/Bono/Busanga

25/30

27/18

0.2123

Hausa

24/27

14/27

0.2996

Both Parents (0/1/2)

413/45/18

327/72/26

0.0006

Both Parents and Sibling (0/1/2/3)

394/54/23/5

300/70/40/15

<0.0001

TOAST-Small

NA

72/82

TOAST-Large

NA

67/90

TOAST-Cardio

NA

28/23

TOAST – Undetermined

NA

31/36

Ethnicity

Family history of hypertension

TOAST Status (M/F)

Author Manuscript

Family History of hypertension (No-member-endorsed / 1-member-endorsed / 2-members-endorsed / 3-members-endorsed) Tobacco use was
classified as Yes=current user and stopped after stroke occurred.
No=formally use or never used. NA: Not applicable

Author Manuscript
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CDKN2A/CDKN2B
A

C

IL6

rs1800796

rs2383207

Minor Allele

Gene Name

SNP

1.957
1.886

Model 3
Model 4

2.550
2.513
2.519
2.852
5.047

Model 1
Model 2
Model 3
Model 4
Model 5

1.654

2.006

Model 2

Model 5

1.645

Odds Ratio (OR)

Model 1

Model

1.446

0.906

0.773

0.778

1.027

0.859

0.998

1.038

1.065

0.971

L95 OR

17.610

8.979

8.213

8.116

6.331

3.184

3.564

3.690

3.777

2.789

U95 OR

0.011

0.073

0.126

0.123

0.044

0.132

0.051

0.038

0.031

0.065

P-value

Significant SNP associations and corresponding odds ratio with Confidence Interval (CI) for sex-stratified analysis of Males only.
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No

Fornage et al. (2008)
rs1800796

No
No
Yes

Tong et al. (2010)
rs1800796

Wang et al. (2014)
rs1800796

This Study
rs1800796

No (subjects were all women)

No

Yamada et al. (2006)
rs1800796

Cole et al. (2008)
rs2069832

Sex-stratified analysis

Authors/SNP

C

G

G

C

C

C

Risk Allele

428 ischemic stroke vs 483 controls

227 ischemic stroke vs 622 controls

748 ischemic stroke vs 748 controls

224 ischemic stroke vs 211 controls (women only)

3073 whites vs 571 blacks

636 ischemic stroke vs 2010 controls

Sample size

2.01 (1.06 – 3.78) males only

1.55 (1.01 – 2.37)

1.45 (1.13 – 1.86)

2.5 (1.0 – 6.50)

1.57 (1.15 – 2.14)

1.40 (1.15 – 1.70)

Odds Ratio (95%CI)

Comparative sample size, odds ratio and p – values of studies reporting association of IL-6 with ischemic stroke.

0.031

0.043

0.004

0.050

0.001

<0.001

p-value
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